Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation

被引:224
作者
Berlato, C
Cassatella, MA
Kinjyo, I
Gatto, L
Yoshimura, A
Bazzoni, F
机构
[1] Univ Verona, Dept Pathol, Sect Gen Path, I-37134 Verona, Italy
[2] Kyushu Univ, Med Inst Bioregulat, Fukuoka 812, Japan
关键词
D O I
10.4049/jimmunol.168.12.6404
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Previous studies have shown that IL-10 can induce the expression of the suppressor of cytokine signaling 3 (SOCS-3) mRNA in human monocytes and neutrophils, suggesting that the capacity of IL-10 to inhibit the expression of LPS-inducible proinflammatory genes may depend on SOCS-3 induction. However, no direct experimental evidence has been provided to support such hypothesis. Herein, we show that stable transfection of SOCS-3 into the mouse macrophage cell line J774 resulted in an inhibition of NO, TNF-alpha, IL-6, and GM-CSF secretion in response to LPS at levels similar to those exerted by IL-10 in LPS-stimulated wild-type J774. Constitutive SOCS-3 expression also down-regulated the mRNA expression of inducible NO synthase and IL-6 and impaired the production of TNF-alpha, mainly at a post-transcriptional level. In addition, SOCS-3-transfected cells displayed a constitutive expression of the IL-1R antagonist gene, consistent with the observation that IL-10 enhances IL-1R antagonist mRNA in LPS-stimulated wild-type cells. Furthermore, in peritoneal macrophages harvested from mice carrying heterozygous disruption of the SOCS-3 gene, IL-10 was less effective in repressing LPS-stimulated TNF-alpha and NO production. Taken together, our data show that SOCS-3 inhibits LPS-induced macrophage activation, strongly supporting the idea that it plays a role in the molecular mechanism by which IL-10 down-modulates the effector functions of LPS-activated macrophages. Finally, we show that forced expression of SOCS-3 significantly suppresses the ability of IL-10 to trigger tyrosine phosphorylation of STAT3. Therefore, SOCS-3 functions both as an LPS signal inhibitor and as a negative feedback regulator of IL-10/STAT3 signaling.
引用
收藏
页码:6404 / 6411
页数:8
相关论文
共 45 条
[1]  
Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936
[2]   INTERLEUKIN-10 BUT NOT INTERLEUKIN-4 IS A NATURAL SUPPRESSANT OF CUTANEOUS INFLAMMATORY RESPONSES [J].
BERG, DJ ;
LEACH, MW ;
KUHN, R ;
RAJEWSKY, K ;
MULLER, W ;
DAVIDSON, NJ ;
RENNICK, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :99-108
[3]   INTERLEUKIN-10 IS A CENTRAL REGULATOR OF THE RESPONSE TO LPS IN MURINE MODELS OF ENDOTOXIC-SHOCK AND THE SHWARTZMAN REACTION BUT NOT ENDOTOXIN TOLERANCE [J].
BERG, DJ ;
KUHN, R ;
RAJEWSKY, K ;
MULLER, W ;
MENON, S ;
DAVIDSON, N ;
GRUNIG, G ;
RENNICK, D .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (05) :2339-2347
[4]   LPS and TNFα induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages [J].
Bode, JG ;
Nimmesgern, A ;
Schmitz, J ;
Schaper, F ;
Schmitt, M ;
Frisch, W ;
Hussinger, D ;
Heinrich, PC ;
Graeve, L .
FEBS LETTERS, 1999, 463 (03) :365-370
[5]  
BOGDAN C, 1992, J BIOL CHEM, V267, P23301
[6]   Differential regulation of the stability of cytokine mRNAs in lipopolysaccharide-activated blood monocytes in response to interleukin-10 [J].
Brown, CY ;
Lagnado, CA ;
Vadas, MA ;
Goodall, GJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (33) :20108-20112
[7]   INTERLEUKIN-10 (IL-10) UP-REGULATES IL-1 RECEPTOR ANTAGONIST PRODUCTION FROM LIPOPOLYSACCHARIDE-STIMULATED HUMAN POLYMORPHONUCLEAR LEUKOCYTES BY DELAYING MESSENGER-RNA DEGRADATION [J].
CASSATELLA, MA ;
MEDA, L ;
GASPERINI, S ;
CALZETTI, F ;
BONORA, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (05) :1695-1699
[9]   Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: Evidence for an IL-10-induced pathway that is independent of STAT protein activation [J].
Cassatella, MA ;
Gasperini, S ;
Bovolenta, C ;
Calzetti, F ;
Vollebregt, M ;
Scapini, P ;
Marchi, M ;
Suzuki, R ;
Suzuki, A ;
Yoshimura, A .
BLOOD, 1999, 94 (08) :2880-2889
[10]  
Clarke CJP, 1998, EUR J IMMUNOL, V28, P1719, DOI 10.1002/(SICI)1521-4141(199805)28:05<1719::AID-IMMU1719>3.0.CO